NASDAQ:SYRS - Syros Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$12.35 +0.12 (+0.98 %)
(As of 05/20/2018 04:00 PM ET)
Previous Close$12.35
Today's Range$12.29 - $12.64
52-Week Range$6.30 - $24.38
Volume236,655 shs
Average Volume150,357 shs
Market Capitalization$402.34 million
P/E Ratio-5.80
Dividend YieldN/A
Beta-2.75

About Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals logoSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYRS
CUSIPN/A
Phone617-744-1340

Debt

Debt-to-Equity RatioN/A
Current Ratio5.78
Quick Ratio5.89

Price-To-Earnings

Trailing P/E Ratio-5.80
Forward P/E Ratio-5.61
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.10 million
Price / Sales365.78
Cash FlowN/A
Price / CashN/A
Book Value$3.21 per share
Price / Book3.85

Profitability

EPS (Most Recent Fiscal Year)($2.13)
Net Income$-54,010,000.00
Net MarginsN/A
Return on Equity-67.11%
Return on Assets-57.78%

Miscellaneous

Employees56
Outstanding Shares32,580,000

Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals (NASDAQ:SYRS) posted its earnings results on Monday, March, 12th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.01. View Syros Pharmaceuticals' Earnings History.

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Syros Pharmaceuticals.

What price target have analysts set for SYRS?

8 brokers have issued 12 month price objectives for Syros Pharmaceuticals' shares. Their forecasts range from $10.00 to $33.00. On average, they anticipate Syros Pharmaceuticals' share price to reach $22.4286 in the next twelve months. View Analyst Ratings for Syros Pharmaceuticals.

What are Wall Street analysts saying about Syros Pharmaceuticals stock?

Here are some recent quotes from research analysts about Syros Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. " (5/16/2018)
  • 2. Cann analysts commented, "For 2018 we have adjusted revenue to account for a $10 million upfront payment being carried on the balance sheet rather than being recognized as revenue this year; and we are fine-tuning estimated operating expenses and estimated shares outstanding. As a result, our estimated loss per share is being increased to $2.04 from our prior estimated loss of $1.81. Our estimated revenue and net income for 2019-22 is unchanged. Estimated loss per share is being increased by $0.01 per year in years 2019 and 2020 as a result of slightly reduced estimated shares outstanding." (5/10/2018)

Who are some of Syros Pharmaceuticals' key competitors?

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the folowing people:
  • Dr. Nancy A. Simonian, Pres, CEO & Director (Age 57)
  • Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 64)
  • Dr. David A. Roth M.D., Chief Medical Officer (Age 55)
  • Dr. Jeremy P. Springhorn Ph.D., Chief Bus. Officer (Age 56)
  • Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Has Syros Pharmaceuticals been receiving favorable news coverage?

News articles about SYRS stock have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Syros Pharmaceuticals earned a media sentiment score of 0.08 on Accern's scale. They also assigned media coverage about the company an impact score of 47.92 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (5.07%), BlackRock Inc. (2.86%), JPMorgan Chase & Co. (1.15%), Candriam Luxembourg S.C.A. (0.63%), Northern Trust Corp (0.56%) and Millennium Management LLC (0.50%). Company insiders that own Syros Pharmaceuticals stock include Colleen Elizabeth Desimone, Eric R Olson, Jeremy P Springhorn, Redmile Group, Llc, Richard A Young, Robert Nelsen and Srinivas Akkaraju. View Institutional Ownership Trends for Syros Pharmaceuticals.

Which institutional investors are selling Syros Pharmaceuticals stock?

SYRS stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A.. Company insiders that have sold Syros Pharmaceuticals company stock in the last year include Colleen Elizabeth Desimone, Eric R Olson and Richard A Young. View Insider Buying and Selling for Syros Pharmaceuticals.

Which institutional investors are buying Syros Pharmaceuticals stock?

SYRS stock was bought by a variety of institutional investors in the last quarter, including Redmile Group LLC, BlackRock Inc., Millennium Management LLC, GSA Capital Partners LLP, Northern Trust Corp, JPMorgan Chase & Co., Schwab Charles Investment Management Inc. and The Manufacturers Life Insurance Company . Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn, Redmile Group, Llc, Robert Nelsen and Srinivas Akkaraju. View Insider Buying and Selling for Syros Pharmaceuticals.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $12.35.

How big of a company is Syros Pharmaceuticals?

Syros Pharmaceuticals has a market capitalization of $402.34 million and generates $1.10 million in revenue each year. The company earns $-54,010,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Syros Pharmaceuticals employs 56 workers across the globe.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]


MarketBeat Community Rating for Syros Pharmaceuticals (SYRS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  314
MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe SYRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Syros Pharmaceuticals (NASDAQ:SYRS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Syros Pharmaceuticals in the last 12 months. Their average twelve-month price target is $22.4286, suggesting that the stock has a possible upside of 81.61%. The high price target for SYRS is $33.00 and the low price target for SYRS is $10.00. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.752.86
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.4286$22.4286$23.8343$26.14
Price Target Upside: 81.61% upside79.86% upside139.54% upside59.00% upside

Syros Pharmaceuticals (NASDAQ:SYRS) Consensus Price Target History

Price Target History for Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals (NASDAQ:SYRS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018CannReiterated RatingBuy$28.00HighView Rating Details
3/14/2018HC WainwrightReiterated RatingHold$10.00HighView Rating Details
3/13/2018WedbushReiterated RatingOutperform ➝ Outperform$11.00 ➝ $13.00HighView Rating Details
1/8/2018OppenheimerSet Price TargetBuy$28.00HighView Rating Details
12/11/2017CowenReiterated RatingBuyHighView Rating Details
10/31/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$30.00N/AView Rating Details
10/23/2017Roth CapitalInitiated CoverageNeutral ➝ Neutral$15.00N/AView Rating Details
9/28/2017JMP SecuritiesUpgradeMarket Perform ➝ Outperform$33.00HighView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Syros Pharmaceuticals (NASDAQ:SYRS) Earnings History and Estimates Chart

Earnings by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals (NASDAQ:SYRS) Earnings Estimates

2018 EPS Consensus Estimate: ($1.70)
2019 EPS Consensus Estimate: ($2.18)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.17)($0.16)($0.17)
Q2 20183($0.51)($0.45)($0.48)
Q3 20183($0.53)($0.48)($0.51)
Q4 20183($0.59)($0.49)($0.55)
Q1 20191($0.50)($0.50)($0.50)
Q2 20191($0.53)($0.53)($0.53)
Q3 20191($0.56)($0.56)($0.56)
Q4 20191($0.59)($0.59)($0.59)

Syros Pharmaceuticals (NASDAQ SYRS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($0.50)N/AView Earnings Details
5/10/2018Q1 2018($0.34)($0.48)$3.41 million$0.37 millionViewN/AView Earnings Details
3/12/2018Q4 2017($0.57)($0.58)ViewN/AView Earnings Details
11/8/2017Q3 2017($0.53)($0.53)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.55)($0.52)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.5920)($0.49)$1.10 millionViewN/AView Earnings Details
3/20/2017Q4 2016($0.6360)($0.47)$0.32 millionViewN/AView Earnings Details
11/14/2016Q316($0.54)($0.65)ViewN/AView Earnings Details
8/15/2016Q2 2016($0.56)($5.42)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Syros Pharmaceuticals (NASDAQ:SYRS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Syros Pharmaceuticals (NASDAQ SYRS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 27.80%
Institutional Ownership Percentage: 48.94%
Insider Trading History for Syros Pharmaceuticals (NASDAQ:SYRS)
Institutional Ownership by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals (NASDAQ SYRS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/31/2018Srinivas AkkarajuDirectorBuy209,424$9.55$1,999,999.20View SEC Filing  
12/15/2017Jeremy P SpringhornInsiderBuy15,000$9.08$136,200.00View SEC Filing  
12/14/2017Srinivas AkkarajuDirectorBuy109,774$9.03$991,259.22View SEC Filing  
10/23/2017Colleen Elizabeth DesimoneInsiderSell550$16.06$8,833.00View SEC Filing  
8/14/2017Richard A YoungDirectorSell3,282$22.00$72,204.00420,101View SEC Filing  
8/7/2017Eric R OlsonInsiderSell2,500$23.59$58,975.002,500View SEC Filing  
7/25/2017Eric R OlsonInsiderSell12,500$21.85$273,125.0012,500View SEC Filing  
7/25/2017Richard A YoungDirectorSell3,282$22.09$72,499.38423,383View SEC Filing  
7/6/2016Redmile Group, LlcMajor ShareholderBuy432,746$12.50$5,409,325.00View SEC Filing  
7/6/2016Robert NelsenDirectorBuy400,000$12.50$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Syros Pharmaceuticals (NASDAQ SYRS) News Headlines

Source:
DateHeadline
Syros Pharmaceuticals (SYRS) to Present on Design of Ongoing Phase 1 Clinical Trial of SY-1365 at ASCOSyros Pharmaceuticals (SYRS) to Present on Design of Ongoing Phase 1 Clinical Trial of SY-1365 at ASCO
www.streetinsider.com - May 17 at 10:38 AM
Syros to Present on Design of Ongoing Phase 1 Clinical Trial of SY-1365 at Upcoming ASCO Annual MeetingSyros to Present on Design of Ongoing Phase 1 Clinical Trial of SY-1365 at Upcoming ASCO Annual Meeting
finance.yahoo.com - May 17 at 10:38 AM
Q2 2018 EPS Estimates for Syros Pharmaceuticals (SYRS) Raised by WedbushQ2 2018 EPS Estimates for Syros Pharmaceuticals (SYRS) Raised by Wedbush
www.americanbankingnews.com - May 17 at 6:35 AM
Syros Pharmaceuticals (SYRS) Lowered to Sell at Zacks Investment ResearchSyros Pharmaceuticals (SYRS) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 16 at 11:04 AM
Syros Pharmaceuticals (SYRS) to Post Q2 2018 Earnings of ($0.47) Per Share, Piper Jaffray ForecastsSyros Pharmaceuticals (SYRS) to Post Q2 2018 Earnings of ($0.47) Per Share, Piper Jaffray Forecasts
www.americanbankingnews.com - May 14 at 1:38 AM
Syros Pharmaceuticals (SYRS) Receives Consensus Rating of "Hold" from AnalystsSyros Pharmaceuticals (SYRS) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - May 13 at 5:15 PM
Edited Transcript of SYRS earnings conference call or presentation 10-May-18 12:30pm GMTEdited Transcript of SYRS earnings conference call or presentation 10-May-18 12:30pm GMT
finance.yahoo.com - May 11 at 3:54 PM
Syros Pharmaceuticals (SYRS) Issues  Earnings ResultsSyros Pharmaceuticals (SYRS) Issues Earnings Results
www.americanbankingnews.com - May 11 at 2:50 PM
Syros Pharmaceuticals (SYRS) Earns "Buy" Rating from CannSyros Pharmaceuticals (SYRS) Earns "Buy" Rating from Cann
www.americanbankingnews.com - May 10 at 1:28 PM
Syros Pharmaceuticals misses by $0.09, misses on revenueSyros Pharmaceuticals misses by $0.09, misses on revenue
seekingalpha.com - May 10 at 10:41 AM
Syros Reports First Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming MilestonesSyros Reports First Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
finance.yahoo.com - May 10 at 10:41 AM
Syros Pharmaceuticals (SYRS) to Release Quarterly Earnings on MondaySyros Pharmaceuticals (SYRS) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - May 7 at 1:38 AM
Syros to Report First Quarter 2018 Financial Results on Thursday, May 10, 2018Syros to Report First Quarter 2018 Financial Results on Thursday, May 10, 2018
finance.yahoo.com - May 3 at 10:12 AM
Syros Takes The Road Less Traveled In Gene Control, Awaits Windfall From Diverse IndicationsSyros Takes The Road Less Traveled In Gene Control, Awaits Windfall From Diverse Indications
www.benzinga.com - April 26 at 10:17 AM
Syros Pharmaceuticals (SYRS) Expected to Post Quarterly Sales of $3.41 MillionSyros Pharmaceuticals (SYRS) Expected to Post Quarterly Sales of $3.41 Million
www.americanbankingnews.com - April 26 at 5:48 AM
Vascular Biogenics (VBLT) and Syros Pharmaceuticals (SYRS) Head-To-Head ComparisonVascular Biogenics (VBLT) and Syros Pharmaceuticals (SYRS) Head-To-Head Comparison
www.americanbankingnews.com - April 24 at 5:14 PM
Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian CancerSyros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer
finance.yahoo.com - April 24 at 10:19 AM
BidaskClub Downgrades Syros Pharmaceuticals (SYRS) to HoldBidaskClub Downgrades Syros Pharmaceuticals (SYRS) to Hold
www.americanbankingnews.com - April 24 at 9:58 AM
Zacks: Analysts Expect Syros Pharmaceuticals (SYRS) Will Announce Earnings of -$0.34 Per ShareZacks: Analysts Expect Syros Pharmaceuticals (SYRS) Will Announce Earnings of -$0.34 Per Share
www.americanbankingnews.com - April 24 at 1:14 AM
Syros Pharmaceuticals (SYRS) Given Average Rating of "Hold" by AnalystsSyros Pharmaceuticals (SYRS) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 18 at 7:24 PM
Syros Pharmaceuticals (SYRS) Upgraded by ValuEngine to "Hold"Syros Pharmaceuticals (SYRS) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - April 17 at 10:21 PM
Syros Pharmaceuticals (SYRS) Cut to Hold at Zacks Investment ResearchSyros Pharmaceuticals (SYRS) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 17 at 12:04 AM
Incyte Advances R&D Strategy with Multiple PartnershipsIncyte Advances R&D Strategy with Multiple Partnerships
finance.yahoo.com - April 12 at 11:24 AM
This May Be The Best Time To Look At IncyteThis May Be The Best Time To Look At Incyte
seekingalpha.com - April 11 at 3:45 PM
Syros Pharmaceuticals (SYRS) Downgraded by JMP SecuritiesSyros Pharmaceuticals (SYRS) Downgraded by JMP Securities
www.americanbankingnews.com - April 11 at 12:42 AM
Syros Pharmaceuticals (SYRS) Expected to Announce Quarterly Sales of $5.05 MillionSyros Pharmaceuticals (SYRS) Expected to Announce Quarterly Sales of $5.05 Million
www.americanbankingnews.com - April 9 at 4:27 AM
 Analysts Expect Syros Pharmaceuticals (SYRS) to Post -$0.34 EPS Analysts Expect Syros Pharmaceuticals (SYRS) to Post -$0.34 EPS
www.americanbankingnews.com - April 7 at 3:26 AM
Syros Pharmaceuticals (SYRS) Raised to "Hold" at Zacks Investment ResearchSyros Pharmaceuticals (SYRS) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 6 at 10:22 PM
Syros Pharmaceuticals (SYRS) Downgraded by BidaskClub to "Hold"Syros Pharmaceuticals (SYRS) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 6 at 10:46 AM
Syros Pharmaceuticals (SYRS) Receives Overweight Rating from Piper JaffraySyros Pharmaceuticals (SYRS) Receives Overweight Rating from Piper Jaffray
www.americanbankingnews.com - April 2 at 8:04 PM
Syros Pharmaceuticals (SYRS) Lowered to Hold at Zacks Investment ResearchSyros Pharmaceuticals (SYRS) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 28 at 7:06 PM
Incyte’s Collaborations and Developments in 2018Incyte’s Collaborations and Developments in 2018
finance.yahoo.com - March 26 at 11:05 AM
Syros Pharmaceuticals (SYRS) Given Consensus Rating of "Buy" by BrokeragesSyros Pharmaceuticals (SYRS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 24 at 7:33 PM
BidaskClub Upgrades Syros Pharmaceuticals (SYRS) to "Sell"BidaskClub Upgrades Syros Pharmaceuticals (SYRS) to "Sell"
www.americanbankingnews.com - March 24 at 3:52 PM
Syros Pharmaceuticals (SYRS) Rating Increased to Buy at BidaskClubSyros Pharmaceuticals (SYRS) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 22 at 9:48 AM
 Brokerages Anticipate Syros Pharmaceuticals (SYRS) to Post -$0.34 Earnings Per Share Brokerages Anticipate Syros Pharmaceuticals (SYRS) to Post -$0.34 Earnings Per Share
www.americanbankingnews.com - March 21 at 3:12 AM
Q2 2018 Earnings Forecast for Syros Pharmaceuticals Inc (SYRS) Issued By WedbushQ2 2018 Earnings Forecast for Syros Pharmaceuticals Inc (SYRS) Issued By Wedbush
www.americanbankingnews.com - March 16 at 8:51 AM
Syros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual MeetingSyros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual Meeting
finance.yahoo.com - March 15 at 11:12 AM
Syros Pharmaceuticals Inc (SYRS) to Post Q1 2018 Earnings of ($0.17) Per Share, Oppenheimer ForecastsSyros Pharmaceuticals Inc (SYRS) to Post Q1 2018 Earnings of ($0.17) Per Share, Oppenheimer Forecasts
www.americanbankingnews.com - March 15 at 6:26 AM
Syros Pharmaceuticals (SYRS) Earns Hold Rating from HC WainwrightSyros Pharmaceuticals (SYRS) Earns Hold Rating from HC Wainwright
www.americanbankingnews.com - March 14 at 3:14 PM
Wedbush Boosts Syros Pharmaceuticals (SYRS) Price Target to $13.00Wedbush Boosts Syros Pharmaceuticals (SYRS) Price Target to $13.00
www.americanbankingnews.com - March 13 at 3:51 PM
Syros Pharmaceuticals (SYRS) Announces Quarterly  Earnings Results, Misses Estimates By $0.01 EPSSyros Pharmaceuticals (SYRS) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - March 13 at 10:56 AM
BRIEF-Syros Announces Appointment Of Joseph J. Ferra As Chief Financial OfficerBRIEF-Syros Announces Appointment Of Joseph J. Ferra As Chief Financial Officer
www.reuters.com - March 12 at 3:42 PM
Syros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated MilestonesSyros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
finance.yahoo.com - March 12 at 8:02 AM
Syros Announces Appointment of Joseph J. Ferra as Chief Financial OfficerSyros Announces Appointment of Joseph J. Ferra as Chief Financial Officer
finance.yahoo.com - March 12 at 8:02 AM
Syros Pharmaceuticals (SYRS) Stock Rating Upgraded by BidaskClubSyros Pharmaceuticals (SYRS) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 10 at 11:00 AM
Syros to Present at Upcoming Investor ConferencesSyros to Present at Upcoming Investor Conferences
finance.yahoo.com - March 5 at 11:27 AM
-$0.57 EPS Expected for Syros Pharmaceuticals Inc (SYRS) This Quarter-$0.57 EPS Expected for Syros Pharmaceuticals Inc (SYRS) This Quarter
www.americanbankingnews.com - March 3 at 11:14 PM
Syros Pharmaceuticals Inc (SYRS) Given Consensus Rating of "Buy" by AnalystsSyros Pharmaceuticals Inc (SYRS) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - February 27 at 7:44 PM
Syros Pharmaceuticals Inc (SYRS) Shares Bought by ARK Investment Management LLCSyros Pharmaceuticals Inc (SYRS) Shares Bought by ARK Investment Management LLC
www.americanbankingnews.com - February 27 at 4:24 AM

SEC Filings

Syros Pharmaceuticals (NASDAQ:SYRS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Syros Pharmaceuticals (NASDAQ SYRS) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.